Skip to main content
DEINOVE logo

DEINOVE — Investor Relations & Filings

Ticker · ALDEI ISIN · FR0010879056 LEI · 969500BEJSRFER0F2K08 PA Professional, scientific and technical activities
Open in API
Filings indexed 300 across all filing types
Latest filing 2015-02-25 Regulatory Filings
Country FR France
Listing PA ALDEI

About DEINOVE

https://www.deinove.com

DEINOVE is a biotechnology company that discovers, develops, and produces high-value compounds derived from rare bacteria and microorganisms, often referred to as 'microbial dark matter'. Leveraging a proprietary technology platform, the company harnesses the metabolic potential of extremophilic bacteria, such as Deinococcus, to create innovative solutions. Its primary applications are focused on developing novel bio-based active ingredients, including carotenoids, for the cosmetics sector, and discovering new antibiotics to address the global challenge of antimicrobial resistance.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 1% confidence The document is a press release dated February 25, 2015, announcing specific corporate developments: the granting of a patent in the United States, membership in the BIO association, and commentary on the US ethanol market. It is not a comprehensive financial report (like 10-K or IR), nor is it a transcript (CT) or a formal regulatory filing detailing insider trades (DIRS) or capital changes (SHA/POS). It is an announcement of strategic business updates, intellectual property protection, and industry engagement. This type of announcement, which details strategic progress and market positioning rather than just financial results (ER) or management changes (MANG), fits best under the general category of Investor Relations or Regulatory Filings. Given the options, since it is a specific, non-financial, non-management announcement, it is most appropriately classified as a general Regulatory Filing (RNS) or potentially an Investor Relations document if that were an option. Since RNS is the designated fallback for miscellaneous regulatory announcements that don't fit elsewhere, and this is a press release detailing strategic moves, RNS is the most suitable code.
2015-02-25 English
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 1% confidence The document is a press release dated January 21, 2015, announcing that DEINOVE has successfully completed the first key milestone of its DEINOCHEM program and will receive 1 million Euros as a repayable advance from ADEME. It details scientific progress, quotes the CEO, and includes standard 'About Us' and 'Contacts' sections typical of corporate news releases. This content does not fit the definitions for a formal financial report (10-K, IR, ER, MRQ), a specific regulatory filing (DVA, DIRS), or a presentation (IP). It is a general corporate update regarding a specific project milestone and associated funding. Since it is a formal announcement of a business/project update that doesn't fit the more specific categories like Earnings Release (ER) or Capital Update (CAP), the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for general corporate announcements not covered elsewhere.
2015-01-21 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Capital/Financing Update Classification · 1% confidence The document is a press release dated January 21, 2015, announcing that DEINOVE has successfully completed a key milestone (Step 1) in its DEINOCHEM program funded by ADEME and will receive 1 million Euros. This type of announcement, detailing operational progress, funding milestones, and strategic updates, is characteristic of an Earnings Release (ER) or a general corporate update. Since it is not a full annual report (10-K), a detailed interim report (IR), a transcript (CT), or a specific regulatory filing like a Director's Dealing (DIRS) or Proxy Statement (PSI), the most appropriate classification is Earnings Release (ER), as these often contain operational highlights and financial updates related to recent performance or milestones, even if they aren't strictly quarterly results. Given the context of a biotech company announcing a milestone payment, ER is the best fit among the provided options for a significant, periodic operational/financial update announcement.
2015-01-21 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 1% confidence The document is a press release dated December 10, 2014, announcing that DEINOVE has been granted five new patents related to its 2G ethanol technology (DEINOL process). It discusses intellectual property, technological basis, and geographical coverage. This type of announcement, focusing on specific corporate developments (like patent grants or strategic updates) that are not standard periodic financial reports (10-K, IR, ER), typically falls under general regulatory announcements or investor relations material. Since it is a specific announcement about technology and IP, it is not a standard financial report, earnings release, or management discussion. It is not a proxy statement (DEF 14A), director dealing (DIRS), or capital change (CAP). Given the content is a specific corporate update intended for investors and the public, and it doesn't fit the highly specific categories like M&A (TAR) or Dividend (DIV), it is best classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were a slide deck, but as a press release detailing strategic news, RNS is the most appropriate fallback for non-standard announcements.
2014-12-10 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and announces that DEINOVE has obtained new key patents protecting its core technology for 2G ethanol production. It details the granting of five specific patents in various jurisdictions (China, Eurasia, Ukraine, South Africa) and provides context on the company's overall intellectual property portfolio. This type of announcement, focusing on specific corporate developments (like IP protection) released via press release, does not fit the definitions for formal financial reports (10-K, IR, ER, MRQ) or specific corporate actions (DIV, SHA, CAP). Since it is a general corporate update released to the public, and it is not a transcript (CT) or a management discussion (MDA), the most appropriate classification is the general regulatory/corporate announcement fallback category, RNS (Regulatory Filings), as it is a formal communication of a significant, non-financial event.
2014-12-10 French
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Share Issue/Capital Change Classification · 1% confidence The document text is an announcement dated December 1, 2014, detailing that DEINOVE has established a maximum 15 million Euro equity financing line with KEPLER CHEUVREUX, structured in four tranches, with the first tranche of 3.5 million Euros executed immediately. This announcement concerns fundraising, capital structure changes, and financing activities. This directly matches the definition for 'Capital/Financing Update' (Code: CAP). It is not a full annual report (10-K), an earnings release (ER), or a simple dividend notice (DIV).
2014-12-01 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.